Endologix Inc.

278 articles with Endologix Inc.

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on December 5, 2018

  12/13/2018

  Endologix, Inc. announced today the grant of inducement equity awards to three newly hired employees (together, the “Awardees”).

• Endologix Honors Innovators of Aortic Therapy at VEITHsymposium

  11/15/2018

  Endologix, Inc. today honored four innovators of aortic therapy at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium®), a meeting of endovascular specialists highlighting developments in the treatment of vascular disease.

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on November 6, 2018

  11/8/2018

  Endologix, Inc. announced today the grant of inducement equity awards to three newly hired employees (together, the “Awardees”).

• Endologix Reports Third Quarter 2018 Financial Results

  11/1/2018

  Endologix, Inc. today announced financial results for the third quarter ended September 30, 2018.

• Endologix, Inc. to Present at Two Investor Conferences in November

  10/29/2018

  Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will present at the following two investor conferences in November:

• Endologix Announces Pricing of Public Offering of Common Stock for Net Proceeds of $20.0 million

  10/25/2018

  Endologix, Inc. announced today the pricing of a registered underwritten public offering of its common stock for net proceeds of $20.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Endologix.

• Endologix Announces Public Offering of Common Stock

  10/24/2018

  Endologix, Inc. (Nasdaq:ELGX) (“Endologix” or the “Company”), developer and marketer of innovative treatments for aortic disorders, announced today that it has commenced a registered underwritten public offering of $20.0 million of its shares of common stock.

• Endologix, Inc. to Announce Third Quarter 2018 Financial Results on November 1, 2018

  10/22/2018

  Endologix, Inc. today announced that it will report financial results for the third quarter of fiscal year 2018 after the market close on Thursday, November 1, 2018.

• FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall

  10/5/2018

  Endologix® Inc. announced today that it has received notice that the U.S. Food and Drug Administration (FDA) has classified a voluntary recall action that Endologix took in July of this year as a Class I recall.

• Endologix Announces Third Quarter Preliminary Revenue Results and Raises Low End of 2018 Revenue Guidance Range

  10/2/2018

  Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the third quarter ended September 30, 2018 is expected to be in the range of $34.3 million to $34.7 million.

• Endologix to Host Investor Meeting on October 2, 2018

  8/23/2018

  Endologix, Inc. announced that it will host a meeting for financial analysts and investment professionals at 4:15 p.m. ET on Tuesday, October 2, 2018, at The London Hotel NYC, 151 W. 54th St., New York, NY 10019.

• Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  8/23/2018

  The awards were approved by the Company’s Compensation Committee

• Endologix Appoints Jeffrey S. Brown as Chief Operations Officer

  8/15/2018

  Endologix, Inc. today announced that it has appointed Jeffrey S. Brown as the Company’s Chief Operations Officer, effective as of August 13, 2018.

• Endologix Reports Second Quarter 2018 Financial Results

  8/9/2018

  Endologix, Inc. announced financial results for the second quarter ended June 30, 2018.

• Endologix Reports Positive 1-Year Results from the Ovation® LUCY Study

  6/28/2018

  Presented in Late-Breaking Session at the Society for Vascular Surgery Annual Meeting

• Endologix Appoints John Onopchenko as Chief Executive Officer

  5/2/2018

  Endologix, Inc. announced that it has appointed John Onopchenko as the Company’s Chief Executive Officer, effective immediately.

• Endologix Reports First Quarter 2018 Financial Results

  5/2/2018

  Endologix, Inc. announced financial results for the first quarter ended March 31, 2018.

• Endologix, Inc. to Announce First Quarter 2018 Financial Results on May 2, 2018

  4/3/2018

  Endologix Inc. announced that it will report financial results for the first quarter of fiscal year 2018 after the market close on Wednesday, May 2, 2018.

• Endologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair (EVAR) Using Ovation Abdominal Stent Graft Systems

  3/19/2018

  Endologix Inc. announced the first results from ENCORE, a pooled, global analysis of several prospective clinical trials and registries studying polymer endovascular aneurysm repair (Polymer EVAR) using Ovation® Abdominal Stent Graft Systems.

• John McDermott Steps Down as Chief Executive Officer of Endologix, Inc.

  2/21/2018

  Endologix, Inc. announced today that John McDermott is stepping down as the Company’s Chief Executive Officer.